Abstract
Purpose: To determine the clinical efficacy of aripiprazole-olanzapine combination treatment in elderly Alzheimer’s disease complicated with mental disorders.
 Methods: Ninety-two elderly patients with Alzheimer’s disease and mental disorders who were admitted to Binzhou People's Hospital, were enrolled in the study. They were randomized into control and study groups. Control group was treated with olanzapine, while the study group was treated with aripiprazole as an adjuvant therapy in addition to olanzapine. The clinical efficacy, scores on different scales (MMSE, ADAS-cog, CDR, ADL, NPI and CMAI), and incidence of adverse reactions were determined.
 Results: The overall degree of response was significantly higher in the study group than in the control group (p < 0.05). There were no significant differences in MMSE, ADAS-cog, CDR, ADL, NPI and CMAI scores between the two groups before treatment (p > 0.05). The MMSE score of the study group was significantly higher than that of the control group, and the scores in the other scales in the study group were significantly lower after treatment (p < 0.05). The study group had significantly lower incidence of adverse reactions than control group (p < 0.05).
 Conclusion: Aripiprazole-olanzapine combination has significant therapeutic benefit in the treatment of elderly Alzheimer’s disease patients complicated with mental disorders. It promotes recovery of neurological function, as well as produces a lower incidence of adverse reactions.
 Keywords: Aripiprazole, Olanzapine, Alzheimer’s disease, Mental disorders
Highlights
Alzheimer’s disease is a progressive, multi-site and multi-nervous function degenerative disease which often occurs in the pre-elderly or elderly population
Ninety-two elderly patients with Alzheimer’s disease and mental disorders who were admitted to our hospital from August 2017 to August 2018 were selected as the study subjects
The study group had significantly higher mini-mental state examination (MMSE) score than the control group, while scores in ADAS-cog, clinical dementia rating (CDR), activity of daily living scale (ADL), neuropsychiatric inventory (NPI) and Cohen-Mansfield Agitation Inventory (CMAI) were significantly lower. These results show that the aripiprazole-olanzapine combination treatment mitigated the mental symptoms of Alzheimer’s disease patients and inhibited the development of the disease, which is in line with the results of a previous study [19]
Summary
Alzheimer’s disease is a progressive, multi-site and multi-nervous function degenerative disease which often occurs in the pre-elderly or elderly population. Studies show that Alzheimer’s disease patients who are more than 60 years old have different degrees of psycho- behavioral symptoms which affect their lives and those of their family members [3,4]. The incidence of elderly Alzheimer’s disease complicated with mental disorders increases with age [5]. At. Olanzapine, a 5-hydroxytryptamine/dopamine antagonist, has a good therapeutic effect on organic mental disorders, but its effect when used alone is not very satisfactory [7]. A study has shown that atypical anti-psychotic drugs have good compliance and efficacy in the treatment of Alzheimer’s disease [8]. Aripiprazole, a new atypical antipsychotic drug, alleviates symptoms of mental disorders reduces negative symptoms, and improves cognitive function of patients [9]. There are no reports on the combined use of the two drugs in clinics
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
